159 related articles for article (PubMed ID: 27118441)
41. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
Takahashi N; Yamada Y; Taniguchi H; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
Arch Med Res; 2014 Jul; 45(5):366-74. PubMed ID: 24830936
[TBL] [Abstract][Full Text] [Related]
42. A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities.
Gamucci T; Nelli F; Cianci G; Grassi G; Moscetti L; Sperduti I; Zeuli M; Cortesi E; D'Auria G; Pollera CF
Clin Colorectal Cancer; 2008 Jul; 7(4):273-9. PubMed ID: 18650196
[TBL] [Abstract][Full Text] [Related]
43. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
[TBL] [Abstract][Full Text] [Related]
44. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
45. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
Soda H; Maeda H; Hasegawa J; Takahashi T; Hazama S; Fukunaga M; Kono E; Kotaka M; Sakamoto J; Nagata N; Oba K; Mishima H
BMC Cancer; 2015 Oct; 15():695. PubMed ID: 26467662
[TBL] [Abstract][Full Text] [Related]
46. Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.
Ooki A; Morita S; Iwamoto S; Hara H; Tanioka H; Satake H; Kataoka M; Kotaka M; Kagawa Y; Nakamura M; Shingai T; Ishikawa M; Miyake Y; Suto T; Hashiguchi Y; Yabuno T; Sakamoto J; Tsuji A; Ando M; Yamaguchi K
Cancer Med; 2020 Mar; 9(5):1779-1789. PubMed ID: 31962002
[TBL] [Abstract][Full Text] [Related]
47. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours.
Bowles DW; Ma WW; Senzer N; Brahmer JR; Adjei AA; Davies M; Lazar AJ; Vo A; Peterson S; Walker L; Hausman D; Rudin CM; Jimeno A
Br J Cancer; 2013 Sep; 109(5):1085-92. PubMed ID: 23942080
[TBL] [Abstract][Full Text] [Related]
48. Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer.
Kogawa T; Doi A; Shimokawa M; Fouad TM; Osuga T; Tamura F; Mizushima T; Kimura T; Abe S; Ihara H; Kukitsu T; Sumiyoshi T; Yoshizaki N; Hirayama M; Sasaki T; Kawarada Y; Kitashiro S; Okushiba S; Kondo H; Tsuji Y
Target Oncol; 2015 Mar; 10(1):125-33. PubMed ID: 24859798
[TBL] [Abstract][Full Text] [Related]
49. Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study.
Shacham Shmueli E; Geva R; Yarom N; Hubert A; Keynan R; Kedem TH; Eini M; Tamarkin D; Shirvan M
Support Care Cancer; 2019 Aug; 27(8):3027-3033. PubMed ID: 30607677
[TBL] [Abstract][Full Text] [Related]
50. Radiochemotherapy with or without cetuximab for unresectable esophageal cancer: final results of a randomized phase 2 trial (LEOPARD-2).
Rades D; Bartscht T; Hunold P; Schmidberger H; König L; Debus J; Belka C; Homann N; Spillner P; Petersen C; Kuhnt T; Fietkau R; Ridwelski K; Karcher-Kilian K; Kranich A; Männikkö S; Schild SE; Maderer A; Moehler M
Strahlenther Onkol; 2020 Sep; 196(9):795-804. PubMed ID: 32533228
[TBL] [Abstract][Full Text] [Related]
51. Disagreement between patient- and physician-reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.
Ooki A; Morita S; Tsuji A; Iwamoto S; Hara H; Tanioka H; Satake H; Kataoka M; Kotaka M; Kagawa Y; Nakamura M; Shingai T; Ishikawa M; Miyake Y; Suto T; Hashiguchi Y; Yabuno T; Ando M; Sakamoto J; Yamaguchi K
Cancer Med; 2020 Dec; 9(24):9419-9430. PubMed ID: 33222406
[TBL] [Abstract][Full Text] [Related]
52. Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab.
Baas J; Krens L; Bohringer S; Mol L; Punt C; Guchelaar HJ; Gelderblom H
PLoS One; 2018; 13(12):e0208080. PubMed ID: 30557370
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score.
Gaiser MR; Lorenzen S; Merx K; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Heeger S; Vlassak S; Koch W; Hofheinz RD
Cancer Med; 2019 Aug; 8(9):4169-4175. PubMed ID: 31199595
[TBL] [Abstract][Full Text] [Related]
54. A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study).
Makker V; Recio FO; Ma L; Matulonis UA; Lauchle JO; Parmar H; Gilbert HN; Ware JA; Zhu R; Lu S; Huw LY; Wang Y; Koeppen H; Spoerke JM; Lackner MR; Aghajanian CA
Cancer; 2016 Nov; 122(22):3519-3528. PubMed ID: 27603005
[TBL] [Abstract][Full Text] [Related]
55. A Phase II, Single-Arm, Open-Label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients with Stage IV Metastatic Pancreatic Adenocarcinoma.
Roth MT; Cardin DB; Borazanci EH; Steinbach M; Picozzi VJ; Rosemury A; Wadlow RC; Newman RA; Berlin J
Oncologist; 2020 Oct; 25(10):e1446-e1450. PubMed ID: 32452588
[TBL] [Abstract][Full Text] [Related]
56. Trichomegaly of the eyelashes induced by the epidermal growth factor receptor inhibitor cetuximab in the treatment of metastatic colorectal cancer.
Matos LV; Pissarra A; Malheiro M; Plácido AN
BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 31040141
[No Abstract] [Full Text] [Related]
57. Hypertrichosis, trichomegaly, and androgenic alopecia related to cetuximab treatment.
Turker S; Cilbir E; Karacin C; Altinbas M
J Cancer Res Ther; 2020; 16(3):690-692. PubMed ID: 32719294
[TBL] [Abstract][Full Text] [Related]
58. Comparison of Various Phase I Combination Therapy Designs in Oncology for Evaluation of Early Tumor Shrinkage Using Simulations.
Seurat J; Girard P; Goteti K; Mentré F
CPT Pharmacometrics Syst Pharmacol; 2020 Dec; 9(12):686-694. PubMed ID: 33080100
[TBL] [Abstract][Full Text] [Related]
59. Cetuximab for the treatment of locally advanced and recurrent/metastatic oral cancer: An investigation of distant metastasis.
Naruse T; Yanamoto S; Matsushita Y; Sakamoto Y; Morishita K; Ohba S; Shiraishi T; Yamada SI; Asahina I; Umeda M
Mol Clin Oncol; 2016 Aug; 5(2):246-252. PubMed ID: 27446558
[TBL] [Abstract][Full Text] [Related]
60. Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial.
Gupta A; O'Callaghan CJ; Zhu L; Jonker DJ; Wong RPW; Colwell B; Moore MJ; Karapetis CS; Tebbutt NC; Shapiro JD; Tu D; Booth CM
JCO Oncol Pract; 2023 Jun; 19(6):e859-e866. PubMed ID: 36881786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
